5 news items
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
RYTM
11 Jun 24
price of $39.68 per share. Each option will vest as to 25% of the shares underlying such option on the first anniversary of the applicable date of hire
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
RYTM
3 Jun 24
, or the failure of these collaborations, our reliance on third parties, risks relating to intellectual property, our ability to hire and retain necessary personnel
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
RYTM
3 Jun 24
relating to intellectual property, our ability to hire and retain necessary personnel, general economic conditions, risks related to internal control
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
RYTM
22 May 24
collaborations, or the failure of these collaborations, our reliance on third parties, risks relating to intellectual property, our ability to hire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
RYTM
16 Apr 24
anniversary of the applicable date of hire of each individual, with the remaining 75% vesting in 12 equal quarterly installments over the three years
- Prev
- 1
- Next